Iovance Biotherapeutics Inc

This non-binding management proposal asks shareholders to approve, on an advisory basis, the overall compensation of the company’s named executive officers as disclosed in the proxy statement. Management seeks support to affirm its pay practices — which emphasize pay-for-performance, market benchmarking, significant equity-based incentives, and retention-focused severance and change-in-control provisions — and to validate its compensation philosophy reflected in base salaries, annual bonuses tied to corporate and individual performance metrics, and long-term equity awards. The Compensation Committee has engaged an independent consultant, set target bonus percentages and equity awards, and implemented clawback, insider trading, and other governance policies to address shareholder concerns. Approval would signal shareholder support for management’s executive compensation approach and provide the Compensation Committee with confirmation to continue its current practices; rejection would likely prompt the Company to engage with shareholders and consider modifications. While advisory only and not binding, the vote is meaningful to the Compensation Committee’s evaluation of future compensation decisions and the company’s governance practices. The Board recommends a vote FOR with the rationale that the disclosed arrangements align executive incentives with long-term stockholder value, reward commercial and clinical milestones including the launch and revenue generation of Amtagvi®, and reflect market competitive compensation.

The management proposal asks shareholders to choose the frequency for future advisory 'say on pay' votes; the Board recommends an annual vote. Management argues that annual votes provide timely feedback on executive pay, align with past shareholder preferences, and enhance engagement. The proposal is non-binding; the frequency receiving majority support will be the stockholder recommendation. For governance-minded investors, annual votes enable more frequent accountability and responsiveness to evolving corporate performance and compensation changes; however, some investors prefer biennial or triennial votes to reduce administrative burden. The Board recommends 'one year' as it believes this cadence best supports ongoing dialogue between the company and its shareholders.

Management proposes an amendment to the Company’s 2020 Employee Stock Purchase Plan to add 1,000,000 shares to the plan’s reserve, increasing it from 2.9 million to 3.9 million shares. The Board and Compensation Committee seek shareholder approval primarily to preserve the Company’s ability to offer the ESPP at current participation levels, support recruitment and retention, and promote employee ownership culture following the company’s transition to a commercial-stage biotech with product launches and growing headcount. The amendment seeks a relatively modest increase (~0.2% of outstanding shares) intended to be sufficient for near-term needs while minimizing dilution. The proposal is standard for companies experiencing growth in employee participation; the board recommends approval based on peer practice, expected accounting impacts, and workforce incentive benefits. A 'for' vote aligns with management’s view that the ESPP promotes alignment between employees and stockholders, though shareholders should consider potential dilution and the plan’s accounting treatment when evaluating the proposal.

Management requests shareholder approval for a Charter amendment to increase authorized common shares by 150 million shares (from 500M to 650M) to provide flexibility for future financing, acquisitions, equity compensation, and other corporate needs. The Board's rationale cites limited remaining authorized shares (given outstanding shares, convertible preferred, and reserved shares under equity plans) and the desire to avoid delays or need for additional shareholder votes for future issuances. Approving the amendment will increase the number of shares available for issuance without immediate issuance, but it will permit future dilution of existing holders and could be used defensively or opportunistically by the Board. The amendment contains no changes to rights of existing shares; Delaware law provides no appraisal rights. Shareholders should weigh the tradeoff between greater corporate flexibility and potential dilution, and consider alternative approaches such as targeted financings or seeking narrower authorizations tied to specific uses. The Board recommends approval for strategic and operational flexibility.

This routine management proposal seeks authority to adjourn the Annual Meeting if there are insufficient votes to approve the Charter amendment (Proposal 6) at the scheduled time, allowing the Company to continue soliciting proxies. The Board argues this preserves flexibility to secure the necessary approval without reconvening a separate meeting. The proposal is procedural and generally non-controversial; shareholders should consider that approval effectively empowers the Board to seek further support for a potentially dilutive Charter amendment. The Board recommends a vote FOR to avoid procedural disruption and to enable efficient solicitation if required.